trending Market Intelligence /marketintelligence/en/news-insights/trending/ErtzXlcNm9F2gsV-DhGP7g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Fitch affirms Boston Scientific's long-term issuer default rating

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Fitch affirms Boston Scientific's long-term issuer default rating

Fitch Ratings affirmed Boston Scientific Corp.'s BBB long-term issuer default rating with a stable outlook.

The rating action applies to about $10.9 billion of debt as of Sept. 30.

Marlborough, Mass.-based Boston Scientific's gross debt to EBITDA ratio is currently high due to the largely debt-financed $4.2 billion acquisition of London-based pharmaceutical company BTG Ltd.

Fitch expects that the company will prioritize leverage reduction over share repurchases and reduce it to about 2.5x by the end of 2020. Leverage is a measure of debt a firm uses to finance its operations.

With reduced contingent liability risk, particularly regarding litigation and taxes, Fitch believes the company will have more flexibility to pursue targeted acquisitions without incurring noticeable debt. In addition, Fitch expects Boston Scientific to continue launching new products in the market with focus on shifting to the high-growth markets.

Boston Scientific is a medical device company that provides physicians with devices used in different areas of healthcare.